PFF In The Media

9/11 first responder diagnosed with cancer, then pulmonary fibrosis

Tom Frey, 54, is a retired New York Police Department detective who was diagnosed with Hodgkin’s lymphoma linked to the time he spent at the World Trade Center site and the Staten Island landfill after the 9/11 attacks.

Link to Article

Deaths of 9/11 first responders from ground zero-related illnesses are on the rise — and some diseases are just beginning to take their toll

Like most first responders, former New York City detective Tom Frey is a master of understatement — even when it comes to talking about the World Trade Center terror attacks on 9/11, the most devastating assignment of his life.

Link to Article

The battle to beat the deadly pulmonary fibrosis

Pulmonary fibrosis is a disease that comes with a prognosis of death in just a few years after severe scarring of the lungs.

Link to Article

PFF Summit Awards Highlight PF Research

A record-breaking international attendance of 950 pulmonary fibrosis (PF) patients, healthcare professionals, caregivers and scientists honored researchers at the Pulmonary Fibrosis Foundation’s recent PFF Summit in San Antonio.

Link to Article

Clinic pitches unproven treatments to desperate patients, with tips on raising the cash

By the time he called the Lung Health Institute, Ed Garbutt was desperate. The Dallas computer parts salesman could barely walk the length of his house without gasping for breath. Unable to work, Garbutt, 64, was going broke paying for trips to the emergency room.

Link to Article

Improving Diagnostics for Pulmonary Fibrosis

New diagnostic methods address a source of common urogential health problems.

Link to Article

West Hartford Resident Lobbies Legislators to Drive Disease Research

In late March, West Hartford resident Malcolm “Mal” Doyle held meetings to educate Connecticut legislators about pulmonary fibrosis (PF) – a progressive, debilitating lung disease that causes scarring in the lungs.

Link to Article

Why Pulmonary Fibrosis Is Underdiagnosed

Results of the annual Pulmonary Fibrosis Foundation (PFF) National Awareness Survey this year showed a quarter of 2000 US adults have never even heard of the disease.

Link to Article

Effect of COVID-19 on Pulmonary Fibrosis Clinical Trials: Expert Interview

For patients with chronic diseases such as pulmonary fibrosis, coronavirus disease 2019 (COVID-19) represents a threat beyond the immediate risk of infection.

Link to Article

Inverness Resident Calling Attention To Life-Threatening Disease

Inverness resident Fredrick Schick, an experienced swimmer, is serving as an ambassador for a national organization in an effort to call attention to a life-threatening disease.

Link to Article

Guidance for Using High-Resolution CT for Interstitial Lung Disease

The Pulmonary Fibrosis Foundation (PFF) has issued a position statement that serves as a guide for conducting high-resolution computed tomography (HRCT) of the thorax for interstitial lung disease (ILD).

Link to Article

Driving research and awareness of pulmonary fibrosis: Pulmonary Fibrosis Foundation is leading the path to a cure

Each September, more than 200,000 Americans living with pulmonary fibrosis (PF) unite in elevating the disease profile during Pulmonary Fibrosis Awareness Month.

Link to Article

Pulmonary Fibrosis Awareness Month Shines a Spotlight on Largely Unsuspected Lung Disease

Dry cough. Fatigue. Shortness of breath. Amidst a pandemic, these symptoms appear as tell-tale signs of COVID-19.

Link to Article

Pulmonary Fibrosis: The Unsuspected Disease Affecting Over 200K Americans

While many people have heard of chronic lung diseases like COPD, asthma and cystic fibrosis, few are familiar with the interstitial lung diseases, also called pulmonary fibrosis (PF).

Link to Article

Dr. Sonye Danoff, Facts About Pulmonary Fibrosis

September is National Pulmonary Fibrosis Awareness Month and more than 200,000 Americans are living with pulmonary fibrosis, a lung disease with no known cure.

Link to Article

Know these Pulmonary Fibrosis Risk Factors

October is Healthy Lung Month, an apt time to educate the public about the importance of protecting our lungs against mold, airborne pollutants and smoking – which put hundreds of thousands of Americans at higher risk for pulmonary fibrosis (PF).

Link to Article

Clinical Challenges: Diagnosing Idiopathic Lung Fibrosis

Approval of two antifibrotic drugs for idiopathic pulmonary fibrosis (IPF) -- pirfenidone (Esbriet) and nintedanib (Ofev) -- represented a paradigm shift in the management of the progressive fibrotic disease and potentially other interstitial lung diseases, ushering in the era of therapies that can slow lung scarring progression.

Link to Article

What You Should Know About Pulmonary Fibrosis

Have you heard of pulmonary fibrosis? If you answered no, you are not alone.

Link to Article